Drug intelligence / Profile preview

CERIG siRNA

Development stage
Preclinical
Lead developer
Stony Brook University
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

CERIG siRNA is a small interfering RNA (siRNA) designed to silence the expression of Cancer ER Invasion Gene (CERIG), also known as KIAA1199 or CEMIP (Cell Migration-Inducing Protein). CERIG is a novel endoplasmic reticulum (ER) resident protein that is upregulated in human invasive breast cancer and other solid tumors, where its expression correlates with poor prognosis. Mechanistically, CERIG forms a complex with the ER chaperone GRP78/BiP and promotes ER calcium leakage, leading to increased cytoplasmic calcium levels and subsequent activation of the PKC-MAPK pathway, which drives cancer cell migration, invasion, and metastasis. Silencing of CERIG using CERIG siRNA in aggressive cancer cells disrupts mesenchymal morphogenesis, induces a mesenchymal-to-epithelial transition (MET), and inhibits cancer cell migration and metastasis in vitro and in vivo.

Other names
CEMIP siRNACancer ER Invasion Gene siRNAKIAA1199 siRNAKIAA-1199 siRNAKIAA 1199 siRNA
02

Targets

HYAL (Hyaluronidase family (HYAL))

Beyond the preview

Go deeper on CERIG siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CERIG siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call